Cryo-Cell Receives Acceptance of Compliance Plan from NYSE American
Cryo-Cell announced that the NYSE American has accepted the company's previously submitted plan to regain compliance with continued listing standards. As previously disclosed on March 12, the company was notified that it was not in compliance with Section 1003 (a) of the NYSE American Company Guide because the Company reported (i) a stockholders' deficit as of November 30, 2025, and (ii) net losses in two of its three most recent fiscal years ended November 30, 2023, November 30, 2024 and November 30, 2025. On April 8, the company submitted a plan to address these deficiencies. NYSE Regulation has reviewed and accepted the plan, granting Cryo-Cell a compliance period through September 9, 2027. During this time, the company's common stock will continue to be listed and traded on NYSE American, subject to ongoing review and adherence to the plan's initiatives. There can be no assurance that the company will be able to regain compliance with the NYSE American continued listing standards by the September 9, 2027, Plan Period deadline. If the company fails to regain compliance by such date or fails to make progress consistent with the accepted compliance plan during the Plan Period, the NYSE American may initiate delisting proceedings.
